Allogeneic hematopoietic stem cell transplantation is performed in patients with hematologic malignancies refractory to chemotherapy. However, its e‹cacy is often limited by the development of graft-versus-host disease (GVHD) secondary to the allogeneic interaction of donor T cells with host dendritic cells. On the other hand, the antihost cytotoxicity of donor T cells enhances the graft-versus-tumor (GVT) eŠect. Extracellular adenosine generated by CD73/ecto-5′ -nucleotidase from ATP via AMP plays pleiotropic roles under physiological and pathological conditions by engaging four adenosine receptors. One study recently demonstrated that ATP released from damaged cells exacerbates GVHD by activating the P2X 7 receptor on host dendritic cells. In this review, we summarize our recentˆndings on the immunosuppressive role of extracellular adenosine in GVHD and the GVT eŠect. We have shown that in MHC-mismatched bone marrow transplantation, CD73 deˆciency, particularly in the recipient, enhanced GVHD severity because of excessive donor T-cell expansion. Severe GVHD was enhanced by repeated administration of a CD73 inhibitor or an adenosine receptor antagonist. A competitive engraftment assay identiˆed endogenous A 2A AR signaling in donor T cells as part of a regulatory mechanism by CD73-generated adenosine. Pharmacological inhibition of CD73 enhanced the GVT eŠect against B-cell lymphoma and improved survival in tumor-relapsing mice after transplantation. Along with ourˆndings, we herein introduce a novel concept that CD73-generated adenosine counteracts the ATP-evoked allogeneic immune reaction as a negative regulatory mechanism in GVHD. Pharmacological manipulation of CD73 activity could be a therapeutic strategy to limit GVHD and to preserve the GVT eŠect against hematopoietic malignancy.
and cd73 -/-BALB/c mice were transplanted with 5×10 6 BM cells±10×10 6 splenocytes from cd73 ＋/＋ or cd73 -/-C57BL/6 mice, respectively (n＝12 to 13, p＜ 0.0001). (B) cd73 ＋/＋ and cd73 -/-C57BL/6 mice were transplanted with 5×10 6 BM cells±15×10 6 splenocytes from cd73 ＋/＋ or cd73 -/-BALB/c mice, respectively (n＝10, p＜0.0001). (C) cd73 ＋/＋ BALB/c mice were transplanted with 5×10 6 
＋/＋ and cd73 -/-C57BL/6 mice were transplanted with 5×10 6 BM cells and
4. CD73 による GVHD の発症抑制
近年，ATP が細胞障害に起因して分泌される
danger-associated molecular patterns の 1 つとして ＋ A20 tumor cells was measured as photons over the total body area via bioluminescence imaging (mean±S.E.M.; day 9,  p＝0.0212; day 12,  p＝ 0.0288; day 15, p＝0.0509, n＝4). (C) As in (B), except that the recipient mice received wild-type A20 tumor cells and only 10 5 CD4 ＋ /CD8 ＋ splenic T cells. A control group of mice did not receive A20 tumor cells. Survival was monitored for 5 w (n＝10 to 11, p＝0.0005 for PBS vs. APCP treatment). 16) hicle 投与群に比べて APCP 投与群では腫瘍の増殖 
